Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business And Finance In Brief

Executive Summary

FDA approves Novartis' Extavia for MS: FDA approved on Aug. 17 Novartis' first multiple sclerosis drug Extavia, a branded version of interferon beta-1b, which is sold by Bayer Schering as Betaseron. The approval will enable Novartis to gain experience in the MS market as it prepares to commercialize its more important oral therapy fingolimod (FTY720) (1"The Pink Sheet," Feb. 2, 2009). The drug maker says it will price Extavia lower than other first-line injectable disease-modifying therapies for MS, though it had not released specifics as of Aug. 21. Extavia is approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations and also is indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI). Novartis gained rights to interferon beta-1b from Bayer Schering. It expects to launch Extavia this fall, backed by a patient support program as well as access to a nurse helpline, one-on-one injection training and assistance with insurance coverage

You may also be interested in...



China Releases First Part Of Essential Drug List For Community Health Clinics And Rural Hospitals

SHANGHAI - China's Ministry Of Health released Aug. 18 the first part of the essential drug list for community health organizations, which consists of 205 chemical drugs and biologics as well as 102 traditional Chinese Medicines. The implementation will begin Sept. 21 in 30 percent of the government-run low-tier hospitals and clinics

Novartis Launches Extavia For Practice In MS Market, Preparing For FTY720

Novartis is launching its interferon beta-1b product Extavia not to be competitive in the multiple sclerosis market so much as to get a sales infrastructure up and running for its late-stage oral MS drug fingolimod (FTY720), Pharmaceuticals CEO Joe Jimenez said during the firm's 2008 year-end earnings call Jan. 28

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel